Cryolife Inc (CRY): James Benson , director of Cryolife Inc sold 5,000 shares on May 10, 2016. The Insider selling transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were sold at $12.22 per share for a total value of $61,100.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 19, 2016, C Elkins Ronald (director) sold 1,000 shares at $12.00 per share price.On Mar 4, 2016, James P Mackin (CEO) purchased 10,000 shares at $10.91 per share price.Also, On Mar 1, 2016, David C Gale (VP, Research & Development) sold 150 shares at $9.97 per share price.On Feb 23, 2016, Scott B Capps (VP, Clinical Research) sold 15,000 shares at $10.30 per share price.
Cryolife Inc (CRY) witnessed a volatile trading activity on Tuesday May 10, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $12.32 and reached the intraday high at $12.35. The bulls started the profit booking and pushed the shares to intraday low of $12.17. The trading session was marked by a volume range of 58,851 shares exchanging hands. The 52-week high of the shares is $13 and the 52-week low is $8.94. The market cap of the company stands at $400 M and there are 3,26,13,669 shares in public circulation.
Company has been under the radar of several Street Analysts.Cryolife Inc is Downgraded by Ladenburg Thalmann to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 28, 2016.Cryolife Inc is Resumed by Piper Jaffray to Overweight. The Rating was issued on Apr 21, 2016.Cryolife Inc is Initiated by Canaccord Genuity to Buy and the brokerage firm has set the Price Target at $14. The Rating was issued on Apr 13, 2016.
CryoLife Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue BioFoam PerClot CardioGenesis cardiac laser therapy HeRO Graft and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue is a polymer consisting of bovine blood protein and an agent for cross-linking proteins which was developed for use in cardiac vascular pulmonary and surgical applications. The Company developed BioFoam to seal organs such as the liver and for use in cardiovascular surgeries and provide hemostasis in penetrating wounds and trauma.